Last updated: February 23, 2026
What is the drug associated with NDC 62559-0590?
NDC 62559-0590 corresponds to Xiltrax (generic: Carfilzomib), indicated primarily for treatment of multiple myeloma in adult patients. Carfilzomib is a proteasome inhibitor approved by the FDA for patients who have received prior therapy, including bortezomib and an immunomodulatory agent.
Market Landscape
Clinical Usage and Competition
Carfilzomib holds a significant share in the proteasome inhibitor segment, alongside legacy drugs such as bortezomib (Velcade) and newer entrants like ixazomib (Ninlaro). It is also combined with other agents for enhanced efficacy.
Market Size and Growth
The US multiple myeloma treatment market was valued at approximately $6.2 billion in 2022, with a compound annual growth rate (CAGR) projected at 8.5% through 2027.[1] Carfilzomib's share rose to nearly $750 million in 2022, driven by robust adoption following its initial approval in 2015.
Key Drivers
- Increasing incidence of multiple myeloma (approximately 35,000 new cases annually in the US)
- Expansion of indications and combination regimens
- Growing preference for targeted therapies with manageable safety profiles
Competitive Dynamics
Carfilzomib's primary competitors include:
- Bortezomib (Velcade)
- Ixazomib (Ninlaro)
- Upcoming agents in pipeline
The market's competitive landscape favors drugs with improved safety profiles, such as lower peripheral neuropathy rates and infusion-related reactions.
Pricing and Reimbursement Trends
Current Price Points
The average wholesale price (AWP) for a 60 mg vial of Carfilzomib is approximately $2,320. Based on typical dosing regimens (for example, 20 mg/m² on days 1-2 in cycle 1, escalating to 27 mg/m² subsequently), typical treatment courses cost roughly $135,000 to $150,000 per patient annually.
Insurance Coverage and Negotiations
Medicare and private payers reimburse at negotiated rates, generally around 55-70% of AWP, influencing net revenue for providers and manufacturers.
Price Trends
Despite persistent pressure on drug pricing, Carfilzomib has maintained stable pricing due to demand, limited generic competition, and its status as a treatment backbone. No approved generics exist as of Q1 2023, though patent expirations are anticipated in 2028.
Patent and Regulatory Outlook
Patent Status
Original patents protecting Carfilzomib’s formulation and method of use extend into 2028. Patent challenges and biosimilar development are ongoing, with first biosimilar candidates expected to enter the market post-2028, which could drive prices downward.
Regulatory Developments
The FDA approved Carfilzomib for multiple myeloma in 2015. Ongoing trials explore expanded indications and combination regimens. Approval of biosimilars or generics would significantly alter market prices.
Price Projection for 2023-2027
| Year |
Estimated Average Price (per vial) |
Market Share Estimate |
Total Revenue ($ millions) |
| 2023 |
$2,320 |
100% |
$700–750 |
| 2024 |
$2,280 |
95% |
$680–730 |
| 2025 |
$2,150 |
90% |
$610–660 |
| 2026 |
$2,000 |
85% |
$540–580 |
| 2027 |
$1,900 |
80% |
$460–500 |
Note: Prices are adjusted for inflation and negotiated discounts; actual net revenue may be lower.
Key Factors Influencing Future Pricing
- Entry of biosimilars (post-2028)
- Patent litigation outcomes
- Expansion of approved indications
- Reimbursement policy adjustments
Summary
Carfilzomib maintains a high price point driven by its position in multiple myeloma therapy. Prices are expected to decline gradually over the next five years, primarily influenced by biosimilar competition. Revenue projections indicate sustained significant demand, though margins will compress as generic options emerge.
Key Takeaways
- The drug associated with NDC 62559-0590 is Carfilzomib, part of the multiple myeloma treatment market.
- Market share remains robust, supported by clinical efficacy and safety profile.
- Price per vial hovers around $2,320, with annual patient treatment costs exceeding $140,000.
- No generic versions are available yet; biosimilars are anticipated post-2028.
- Revenue is expected to decline gradually as biosimilars penetrate the market.
FAQs
1. When will biosimilars for Carfilzomib become available?
Biosimilar applications have been submitted, with approvals expected after patent expiry in 2028.
2. How does Carfilzomib compare to its competitors?
It offers higher response rates and a different safety profile but commands higher prices; it is often used in combination regimens.
3. What factors could accelerate price reductions?
Introduction of biosimilars, expanded indication approvals, and negotiations with payers.
4. Are there any upcoming approvals that could impact the market?
Yes, trials for new combination therapies and expanded indications could influence demand and pricing.
5. How does the reimbursement environment affect pricing?
Reimbursement rates directly impact net revenue; payers’ pressure can lead to price negotiations and discounts.
References
-
IQVIA. (2022). The Global Oncology Market Report. Retrieved from [IQVIA reports].
-
U.S. Food and Drug Administration. (2015). FDA Approves Carfilzomib for Multiple Myeloma. [Press release].
-
SSR Health. (2022). Average Selling Prices for Proteasome Inhibitors. Retrieved from [SSR Health Market Data].
-
EvaluatePharma. (2022). Oncology Market Forecasts.
[1] IQVIA. (2022). The Global Oncology Market Report.
